Anacail Ltd, a venture capital-backed spin-out from the University of Glasgow, has secured a £336k Innovate UK grant award under the Biomedical Catalyst scheme to develop a high throughput, scalable and environmentally benign sterilisation technology for medical devices and life science products. The concept builds on Anacail’s core Intellectual Property which can integrate sterilisation and packing into a single process. The project duration is two years, and will allow Anacail to develop a prototype packing machine, which can be used to develop the technology towards market launch.
With increasing medical device complexity customers are looking for alternatives to traditional technologies such as EtO, radiation and steam sterilisation. Anacail generates ozone (an FDA recognised sterilant) on demand and seals it inside the medical device primary pack. The ozone then sterilises the surface of the device and decays back to native oxygen.
The advantages of the process are that it is: residual-free, environmentally-benign, low-temperature (<35C), low-humidity, scalable, point of manufacture with high throughput and has good material compatibility – being able to treat polymers, hydrogels, optics and electronics.
Dr Ian Muirhead, CEO of Anacail, commented: “We are delighted to have secured funding from Innovate UK for this exciting and timely project. Anacail believes it can contribute significantly to the challenges of sterilisation in the next generation of medical devices, particularly in the area of biologics, sensors and lab-on-a-chip applications.
“If you are a company or research organisation seeking alternative sterilisation technologies then Anacail would keen to speak to you.”